Arbor plans to use the proceeds to advance its lead programs in liver and CNS disease into the clinic and progress a pipeline of precision editing therapeutics, while also continuing to invest in its novel discovery engine to develop the next generation of gene editing technology.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

20 Acorn Park Dr. 500
Cambridge, MA 02140
USA

Phone

Undisclosed

Website

www.arbor.bio

Email Address

[email protected]

Overview

We envision a world in which all patients with serious genetic diseases can be treated with curative genetic medicines. We start with the patient in mind, working to understand the underlying genetic pathology of disease.

Profile

Social Media

Arbor Biotechnologies Company Twitter Account

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Devyn Smith

Chief Operating Officer

Pam Stetkiewicz

Chief Scientific Officer

John Murphy

Chief Technical Officer

David Cheng

Co-Founder

David Scott

Vice President

Kelly Morgan

VP - Bus. Development

Kathryn McCabe

Browse more venture capital transactions:

Prev: 11/10/2021: Cheeze venture capital transaction
Next: 11/10/2021: Block Renovation venture capital transaction

Share this article

About Database of VC Transactions

We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are derived from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary